Lagosa

PATIENT LEAFLET: INFORMATION FOR THE USER

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Lagosa

Effervescent tablets
Silybi mariani extractum siccum
Read the entire leaflet carefully, as it contains important information for the patient.
This medication is available without a prescription. However, to achieve the best treatment results, the medication
Lagosa should be used cautiously.

• Keep this leaflet, so you can read it again if needed.
• Consult a pharmacist if you need advice or additional information.
• If symptoms worsen or do not improve, consult a doctor.
• If any of the side effects worsen or if any side effects not mentioned in the leaflet occur, tell your doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is Lagosa and what is it used for
• 2. Important information before using Lagosa
• 3. How to use Lagosa
• 4. Possible side effects
• 5. How to store Lagosa
• 6. Contents of the packaging and other information

1. WHAT IS LAGOSA AND WHAT IS IT USED FOR

Lagosa is a medication that protects the liver from the effects of toxic compounds, stimulates its
regenerative ability, prevents the penetration of hepatotoxic factors into liver cells, stabilizes and normalizes liver cell functions.
Indications for use:
Conditions after liver damage caused by toxic compounds; as a supportive treatment in chronic inflammatory liver conditions.

2. IMPORTANT INFORMATION BEFORE USING LAGOSA

Do not use if you are hypersensitive to the active or excipient substances contained in the product.
Use in children:
Due to the lack of safety data, it is not recommended to use in children under 12 years of age.
The medication contains lactose monohydrate and sucrose; if you have previously been diagnosed with intolerance to certain sugars, you should consult your doctor before taking the medication.
The medication contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".

Using other medications

No interactions with other medications have been found.

Pregnancy and breastfeeding

Due to the lack of safety data, it is not recommended to use during pregnancy and breastfeeding.

Driving and operating machinery

No data available.

3. HOW TO USE LAGOSA

Adults and children over 12 years: one effervescent tablet twice a day.
Tablets should be taken with a sufficient amount of liquid.

Using a higher dose of Lagosa than recommended

No cases of poisoning have been reported.
No antidote is known in case of overdose. Symptomatic treatment should be initiated.

4. POSSIBLE SIDE EFFECTS

Like all medications, Lagosa can cause side effects, although not everybody will experience them.
In case of side effects, stop using the medication and consult a doctor.
A mild laxative effect occurs occasionally.

Reporting side effects

If you experience any side effects, including those not mentioned in the leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects will help gather more information on the safety of the medication.

5. HOW TO STORE LAGOSA

Store the medication in a place invisible and inaccessible to children.
Do not use Lagosa after the expiration date stated on the packaging.
The expiration date refers to the last day of the specified month.
Store at a temperature below 25°C.
Medications should not be disposed of in sewage or household waste containers. Ask your pharmacist how to dispose of unused medications. This will help protect the environment.

6. CONTENTS OF THE PACKAGING AND OTHER INFORMATION

What Lagosa contains

The active substance is 240.0 mg of dry extract of milk thistle (Frukt. Cardui mariae)
corresponding to 150 mg of silymarin calculated as silybin.
Excipients:
Tablet core: lactose monohydrate, microcrystalline cellulose, anhydrous colloidal silica, sodium croscarmellose, povidone K 30, talc, magnesium stearate, partial glycerides.
Tablet coating: shellac, sucrose, calcium carbonate, talc, arabic gum, corn starch, titanium dioxide, anhydrous colloidal silica, povidone K 30, macrogol 6000, glycerol 85%, polysorbate 80, montan glycol wax.
Does not contain gluten.
Contains lactose monohydrate and sucrose.
Considered "sodium-free".

What Lagosa looks like and what the packaging contains

Round effervescent tablets.
Al/PVC blisters in a cardboard box.
Packaging contains: 25, 50, or 100 effervescent tablets.
For more detailed information, consult the marketing authorization holder or parallel importer.

Marketing authorization holder in the Czech Republic, the country of export:

Wörwag Pharma GmbH & Co. KG
Flugfeld-Allee 24
71034 Böblingen
Germany

Manufacturer:

Dragenopharm Apotheker Püschl GmbH
Göllstr. 1
84529 Tittmoning
Germany

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in the Czech Republic, the country of export:94/409/97-C
Parallel import authorization number:281/17
Date of leaflet approval: 13.06.2022
[Information about the trademark]